



Test Report/ Certificate of Analysis

Date of Report: Nov 13, 2025
To: Protixa
From: AxisPharm, LLC
Certificate ID Number: 13Nov2025-10

Results reported by: Lab Technician Ning Yang

Review/Approved by: [Signature] QA Director Dawei Yue

Sample Received: Date: 11/10/2025
Receiving Condition: [X] Acceptable [] Other:
Storage Condition: [] Room temperature [] -20°C [] -80°C
[X] Other: 0 °C

Sample Name: NAD+ 300mg; Label mg Claim: 300mg;
Brand Name: Protixa; Lot#: NAD300V1125; MFD: 11/2025;
BBD: 11/2027

Method(s): LCMS and LAL Endotoxin Assay

Procedure(s): Laboratory Activity Date: 11/10/2025

Results:

Table with 5 columns: Sample Name, Net Weight Measured, MW (g/mol), Detected, UV Purity (208nm) (%). Row 1: NAD+ 300mg, 307.5, 663.43, 665.0 [M+H], >99

Endotoxin Results:

Table with 3 columns: Sample Name, Net Weight Measured, Endotoxin Testing Value (EU/mg). Row 1: NAD+ 300mg, 307.5, 0.068

Salts and sugars that serves as fillers in injectables are not considered as impurities.

Conclusion: The product comes with NAD+ 307.5 mg with purity >99.0%.